The role of the gut microbiota in sepsis

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 2, 2017, Pages 135-143

  Haak, Bastiaan W ^a   Wiersinga, W Joost ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ADVERSE OUTCOME; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DYSBIOSIS; FECES MICROFLORA; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; META ANALYSIS (TOPIC); MICROBIAL COLONIZATION; MOLECULARLY TARGETED THERAPY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY;

ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

ADAPTIVE IMMUNITY; ANTI-BACTERIAL AGENTS; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; MULTIPLE ORGAN FAILURE; PROBIOTICS; SEPSIS;

EID: 85012982058     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30119-4     Document Type: Review

References (72)

1. 1 Vincent, JL, Marshall, JC, Namendys-Silva, SA, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med 2 (2014), 380–386.
2. 2 Gotts, JE, Matthay, MA, Sepsis: pathophysiology and clinical management. BMJ, 353, 2016, i1585.
3. 3 Prescott, HC, Osterholzer, JJ, Langa, KM, Angus, DC, Iwashyna, TJ, Late mortality after sepsis: propensity matched cohort study. BMJ, 353, 2016, i2735.
4. 4 Wiersinga, WJ, Leopold, SJ, Cranendonk, DR, van der Poll, T, Host innate immune responses to sepsis. Virulence 5 (2014), 36–44.
5. 5 Singer, M, Deutschman, CS, Seymour, C, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315 (2016), 801–810.
6. 6 Vincent, J-L, Opal, SM, Marshall, JC, Tracey, KJ, Sepsis definitions: time for change. Lancet 381 (2013), 774–775.
7. 7 Hotchkiss, RS, Monneret, G, Payen, D, Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13 (2013), 862–874.
8. 8 Carrico, CJ, Meakins, JL, Marshall, JC, Fry, D, Maier, RV, Multiple-organ-failure syndrome. Arch Surg 121 (1986), 196–208.
9. 9 Klingensmith, NJ, Coopersmith, CM, The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin 32 (2016), 203–212.
10. 10 Zoetendal, EG, Rajilic-Stojanovic, M, de Vos, WM, High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57 (2008), 1605–1615.
11. 11 Ojima, M, Motooka, D, Shimizu, K, et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci 61 (2016), 1628–1634.
12. 12 Zaborin, A, Smith, D, Garfield, K, et al. Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 5 (2014), e01361–e01414.
13. 13 Schuijt, TJ, van der Poll, T, de Vos, WM, Wiersinga, WJ, The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol 21 (2013), 221–229.
14. 14 Sender, R, Fuchs, S, Milo, R, Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164 (2016), 337–340.
15. 15 Turnbaugh, PJ, Hamady, M, Yatsunenko, T, et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
16. 16 van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM 368 (2013), 407–415.
17. 17 Taur, Y, Jenq, RR, Perales, MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124 (2014), 1174–1182.
18. 18 Falony, G, Joossens, M, Vieira-Silva, S, et al. Population-level analysis of gut microbiome variation. Science 352 (2016), 560–564.
19. 19 Zhernakova, A, Kurilshikov, A, Bonder, MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352 (2016), 565–569.
20. 20 Chung, H, Pamp, SJ, Hill, JA, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149 (2012), 1578–1593.
21. 21 Pamer, EG, Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352 (2016), 535–538.
22. 22 Kamada, N, Seo, SU, Chen, GY, Núñez, G, Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 13 (2013), 321–335.
23. 23 Rajilic-Stojanovic, M, de Vos, WM, The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 38 (2014), 996–1047.
24. 24 Clarke, TB, Davis, KM, Lysenko, ES, Zhou, AY, Yu, Y, Weiser, JN, Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nature Med 16 (2010), 228–231.
25. 25 Clarke, TB, Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect Immun 82 (2014), 4596–4606.
26. 26 Blaser, M, Antibiotic overuse: stop the killing of beneficial bacteria. Nature 476 (2011), 393–394.
27. 27 Vincent, JL, Rello, J, Marshall, J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (2009), 2323–2329.
28. 28 Dickson, RP, The microbiome and critical illness. Lancet Respir Med 4 (2016), 59–72.
29. 29 O'Keefe, SJ, Ou, J, Delany, JP, et al. Effect of fiber supplementation on the microbiota in critically ill patients. World J Gastrointest Pathophysiol 2 (2011), 138–145.
30. 30 Furusawa, Y, Obata, Y, Fukuda, S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
31. 31 de Vos, WM, de Vos, EA, Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 70 (2012), 45–56.
32. 32 Krezalek, MA, DeFazio, J, Zaborina, O, Zaborin, A, Alverdy, JC, The shift of an intestinal “microbiome” to a “pathobiome” governs the course and outcome of sepsis following surgical injury. Shock 45 (2016), 475–482.
33. 33 Shimizu, K, Ogura, H, Hamasaki, T, et al. Altered gut flora arev associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 56 (2011), 1171–1177.
34. 34 Osuka, A, Shimizu, K, Ogura, H, et al. Prognostic impact of fecal pH in critically ill patients. Crit Care, 16, 2012, R119.
35. 35 Moore, FA, Moore, EE, Poggetti, R, et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma 31 (1991), 629–636.
36. 36 Badami, CD, Senthil, M, Caputo, FJ, et al. Mesenteric lymph duct ligation improves survival in a lethal shock model. Shock 30 (2008), 680–685.
37. 37 Senthil, M, Watkins, A, Barlos, D, et al. Intravenous injection of trauma-hemorrhagic shock mesenteric lymph causes lung injury that is dependent upon activation of the inducible nitric oxide synthase pathway. Ann Surg 246 (2007), 822–830.
38. 38 Fox, AC, McConnell, KW, Benyam, PY, et al. The endogenous bacteria alter gut epithelial apoptosis and decrease mortality following Pseudomonas aeruginosa pneumonia. Shock 38 (2012), 508–514.
39. 39 Ubeda, C, Taur, Y, Jenq, RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 120 (2010), 4332–4341.
40. 40 Ayres, JS, Trinidad, NJ, Vance, RE, Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 18 (2012), 799–806.
41. 41 Prescott, HC, Dickson, RP, Rogers, MA, Langa, KM, Iwashyna, TJ, Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med 192 (2015), 581–588.
42. 42 Zeng, MY, Cisalpino, D, Varadarajan, S, et al. Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity 44 (2016), 647–658.
43. 43 Proietti, M, Cornacchione, V, Rezzonico Jost, T, et al. ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer's patches to promote host-microbiota mutualism. Immunity 41 (2014), 789–801.
44. 44 Deshmukh, HS, Liu, Y, Menkiti, OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 20 (2014), 524–530.
45. 45 Schuijt, TJ, Lankelma, JM, Scicluna, BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65 (2016), 575–583.
46. 46 Alobaidi, R, Basu, RK, Goldstein, SL, Bagshaw, SM, Sepsis-associated acute kidney injury. Semin Nephrol 35 (2015), 2–11.
47. 47 Jang, HR, Ko, GJ, Wasowska, BA, Rabb, H, The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 87 (2009), 859–864.
48. 48 Andrade-Oliveira, V, Amano, MT, Correa-Costa, M, Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26 (2015), 1877–1888.
49. 49 Hartl, WH, Jauch, KW, Metabolic self-destruction in critically ill patients: origins, mechanisms and therapeutic principles. Nutrition 30 (2014), 261–267.
50. 50 Schieber, AM, Lee, YM, Chang, MW, et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science 350 (2015), 558–563.
51. 51 de Smet, AM, Kluytmans, JA, Cooper, BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360 (2009), 20–31.
52. 52 Price, R, MacLennan, G, Glen, J, for the SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ, 348, 2014, g2197.
53. 53 Oostdijk, EA, de Smet, AM, Blok, HE, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 181 (2010), 452–457.
54. 54 Sommer, MO, Church, GM, Dantas, G, The human microbiome harbors a diverse reservoir of antibiotic resistance genes. Virulence 1 (2010), 299–303.
55. 55 Smillie, CS, Smith, MB, Friedman, J, Cordero, OX, David, LA, Alm, EJ, Ecology drives a global network of gene exchange connecting the human microbiome. Nature 480 (2011), 241–244.
56. 56 Arumugam, S, Lau, CS, Chamberlain, RS, Probiotics and synbiotics decrease postoperative sepsis in elective gastrointestinal surgical patients: a meta-analysis. J Gastrointest Surg 20 (2016), 1123–1131.
57. 57 Bo, L, Li, J, Tao, T, et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev, 10, 2014 CD009066.
58. 58 AlFaleh, K, Anabrees, J, Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 4, 2014 CD005496.
59. 59 Rao, SC, Athalye-Jape, GK, Deshpande, GC, Simmer, KN, Patole, SK, Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics 137 (2016), 1–16.
60. 60 Besselink, MG, van Santvoort, HC, Buskens, E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008), 651–659.
61. 61 Buffie, CG, Bucci, V, Stein, RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
62. 62 Ng, KM, Ferreyra, JA, Higginbottom, SK, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502 (2013), 96–99.
63. 63 Han, S, Shannahan, S, Pellish, R, Fecal microbiota transplant: treatment options for clostridium difficile infection in the intensive care unit. J Intensive Care Med 31 (2015), 577–586.
64. 64 Li, Q, Wang, C, Tang, C, et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care, 19, 2015, 37.
65. 65 Li, Q, Wang, C, Tang, C, et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol 109 (2014), 1832–1834.
66. 66 Tosh, PK, McDonald, LC, Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis 54 (2012), 707–713.
67. 67 Dessein, R, Gironella, M, Vignal, C, et al. Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of Yersinia pseudotuberculosis. Gut 58 (2009), 771–776.
68. 68 La Rosa, PS, Brooks, JP, Deych, E, et al. Hypothesis testing and power calculations for taxonomic-based human microbiome data. PLoS One, 7, 2012, e52078.
69. 69 Lankelma, JM, Cranendonk, DR, Belzer, C, et al. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. Gut, 2016, 10.1136/gutjnl-2016-312132 published online June 15.
70. 70 Pfeiffer, JK, Virgin, HW, Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science, 351, 2016, 10.1126/science.aad5872 published online Jan 14.
71. 71 Huffnagle, GB, Noverr, MC, The emerging world of the fungal microbiome. Trends Microbiol 21 (2013), 334–341.
72. 72 Davenport, EE, Burnham, KL, Radhakrishnan, J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4 (2016), 259–271.